Filing Details

Accession Number:
0000947871-23-000438
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-04-07 16:42:12
Reporting Period:
2023-04-05
Accepted Time:
2023-04-07 16:42:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1800315 Galecto Inc. GLTO () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055951 Orbimed Advisors Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
No No Yes No
1682090 Orbimed Israel Gp Ii, L.p. 5 Hahoshlim Street
Building B, 1St Floor
Herzliya Pituach L3 4614001
No No Yes No
1682093 Ltd Ii Israel Advisors Orbimed 5 Hahoshlim Street
Building B, 1St Floor
Herzliya Pituach L3 4614001
No No Yes No
1760648 Orbimed Capital Gp Vii Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
No No Yes No
1808744 Orbimed Genesis Gp Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-04-05 4,687 $2.18 187,100 No 4 S Indirect See footnotes
Common Stock Disposition 2023-04-05 25,220 $2.18 1,006,591 No 4 S Indirect See footnotes
Common Stock Disposition 2023-04-05 63,058 $2.18 2,516,599 No 4 S Indirect See footnotes
Common Stock Disposition 2023-04-06 487 $2.00 186,613 No 4 S Indirect See footnotes
Common Stock Disposition 2023-04-06 2,620 $2.00 1,003,971 No 4 S Indirect See footnotes
Common Stock Disposition 2023-04-06 6,558 $2.00 2,510,041 No 4 S Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
No 4 S Indirect See footnotes
Footnotes
  1. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis.
  2. These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel") is the general partner of OIP II and OrbiMed Advisors Israel II Limited ("OrbiMed Limited") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II.
  3. These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII.
  4. Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.